Recently, Morgan Stanley Capital International (MSCI), the world’s reputable environmental, social, and governance (ESG) rating institutions, released its 2024 ESG ratings in which Hansoh Pharma achieved an AA rating for the second year in a row, keeping the company at the forefront of the industry.
In this year’s MSCI rating report, Hansoh Pharma advanced across two key issues: "Toxic Emissions and Waste" and "Corporate Behavior," making it a global ESG leader in these two areas for the first time. Now, Hansoh Pharma is recognized as an ESG leader in five key issues, including "Product Safety & Quality," "Corporate Governance," and "Access to Healthcare.”
As one of the world’s most well-recognized ESG index rating institutions, MSCI ratings have become a popular benchmark for investments in international capital markets. Being awarded an AA rating for two years consecutive manifests Hansoh Pharma’s strong commitment to sustainable development and also highlights the company’s exceptional performance in corporate governance, scientific research and innovation, product quality, accessible healthcare, human capital development, community welfare, sustainable supply chain, and low-carbon environmental initiatives.
The company’s ESG governance system is widely acknowledged by global ESG rating agencies and professional medical media. In 2024, Hansoh Pharma was once again included inS&P Global Sustainability Yearbook 2024 and S&P Global Sustainability Yearbook 2024 (China Edition), as the highest-scoring company among industry peers in China’s mainland. Additionally, the company was placed among the Top 20 Chinese Pharmaceutical Listed Companies in ESG Competitiveness (Large-Cap) by Healthcare Executive for three consecutive years, and ranked first in the "Top 10 Low-Carbon Pioneers of Chinese Pharmaceutical Listed Companies”.
Fulfilling social responsibilities is key for companies to achieve sustainable development, and continually generating value long term is beneficial for all parties concerned. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will actively respond to the United Nations Sustainable Development Goals, continuously implement advanced ESG practices and make greater contributions to the long-term development of the global economy, environment, and society.
